sellWeak10b5-1 plan
Theresa Wingrove sold $5.6M of IMGN
SVP OF REGULATORY AFFAIRS at ImmunoGen, Inc.. 187,667 shares at an average of $29.64, traded Jan 16, 2024, filed Jan 18, 2024.
Warning score
25Value
$5.6M
187,667 shares
Holdings after
3,426
-98% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$5.6M at market
- +20Share of holdings soldSold 98% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-001545, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 16, 2024 | MOption exercise Common Stock10b5-1 | +58,900 | $4.83 | $284k | 62,326 | Jan 18, 2024 |
| Jan 16, 2024 | MOption exercise Common Stock10b5-1 | +2,667 | $5.75 | $15k | 64,993 | Jan 18, 2024 |
| Jan 16, 2024 | MOption exercise Common Stock10b5-1 | +126,100 | $5.25 | $662k | 191,093 | Jan 18, 2024 |
| Jan 16, 2024 | SOpen-market sale Common Stock10b5-1 | -187,667 | $29.64 | $5.6M | 3,426 | Jan 18, 2024 |
| Jan 16, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -58,900 | $0.00 | $0 | 0 | Jan 18, 2024 |
| Jan 16, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,667 | $0.00 | $0 | 1,333 | Jan 18, 2024 |
| Jan 16, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -126,100 | $0.00 | $0 | 0 | Jan 18, 2024 |
Related signals
Other insiders at ImmunoGen, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | ImmunoGen, Inc. | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER | $134k 4,583 shares | -6% | |
| 24Weak | ImmunoGen, Inc. | Mark J Enyedy CHIEF EXECUTIVE OFFICER | $589k 20,107 shares | -3% | |
| 8Weak | ImmunoGen, Inc. | Renee Lentini VP & PRIN ACCTG OFFICER | $77k 2,631 shares | -15% | |
| 20Weak | ImmunoGen, Inc. | Theresa Wingrove SVP OF REGULATORY AFFAIRS | $352k 12,027 shares | -36% | |
| 10Weak | ImmunoGen, Inc. | Renee Lentini VP & PRIN ACCTG OFFICER | $195k 6,548 shares | -44% | |
| 33Weak | ImmunoGen, Inc. | Theresa Wingrove SVP OF REGULATORY AFFAIRS | $3.5M 117,445 shares | -98% | |
| 25Weak | ImmunoGen, Inc. | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER | $112k 3,826 shares | -10% | |
| 34Weak | ImmunoGen, Inc. | Kristine Peterson director | $578k 20,000 shares | -100% | |
| 40Moderate | ImmunoGen, Inc. | Theresa Wingrove SVP OF REGULATORY AFFAIRS | $4.9M 171,216 shares | -1783% | |
| 40Moderate | ImmunoGen, Inc. | Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER | $1.7M 108,609 shares | -172% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.